Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Systemic vasculitis

From Wikipedia, the free encyclopedia
Medical condition
Systemic vasculitis
Other namesNecrotizing vasculitis
A case ofvasculitis on legs
SpecialtyImmunology,rheumatology

Necrotizing vasculitis, also calledsystemic necrotizing vasculitis,[1] is a general term for theinflammation ofveins andarteries that develops intonecrosis and narrows the vessels.[2]

Tumors, medications,allergic reactions, and infectious organisms are some of the recognized triggers for these conditions, even though the precise cause of many of them is unknown. Immune complex disease,anti-neutrophil cytoplasmic antibodies, anti-endothelial cell antibodies, and cell-mediated immunity are examples of pathogenetic factors.[2]

Numerous secondary symptoms of vasculitis can occur, such asthrombosis,aneurysm formation, bleeding, occlusion of an artery, loss of weight,exhaustion,depression, fever, and widespread pain that worsens in the morning.[2]

Systemic vasculitides are categorized as small, medium, large, or variable based on the diameter of the vessel they primarily affect.[3]

Classification

[edit]

Large-vessel vasculitis

[edit]

The 2012Chapel Hill Consensus Conference defines large vessel vasculitis (LVV) as a type of vasculitis that can affect any sizeartery, but it usually affects the aorta and its major branches more frequently than other vasculitides.[4]Takayasu arteritis (TA) andgiant cell arteritis (GCA) are the two main forms of LVV.[5]

Takayasu arteritis (TA) is a large-vessel, idiopathic, granulomatous arteritis that primarily affects theaorta, significant branches of it, and (less frequently) thepulmonary arteries.[6] The disease's symptoms can range from catastrophic neurological impairment to an asymptomatic condition brought on by impalpable pulses orbruits.[7] Non-specific features include mildanemia,myalgia,arthralgia,weight loss,malaise,night sweats, andfever.[8]

Giant cell arteritis (GCA) is the most common type of systemic vasculitis in adults.Polymyalgia rheumatica (PMR), headache,jaw claudication, and visual symptoms are the classic manifestations; however, 40% of patients present with a variety of occult manifestations.[9]

Medium vessel vasculitis

[edit]

Medium vessel vasculitis is a type of vasculitis that mostly affects the mediumarteries, which are the major arteries that supply theviscera and their branches. Any size artery could be impacted, though.[4] The two primary types arepolyarteritis nodosa andKawasaki disease.[5]

Polyarteritis nodosa is a type of systemic necrotizing vasculitis that primarily affects arteries of medium size. While small vessels likearterioles,capillaries, andvenules are not affected, smallarteries can be. The disease spectrum varies from failure of multiple organs to involvement of a single organ. Almost any organ could be impacted; however,polyarteritis nodosa rarely affects thelungs for unknown reasons.[10]

Kawasaki disease is a type of systemic vasculitis of medium-sized vessels with an acute onset that primarily affects young children.Fever,conjunctivitis, infection of the skin andmucous membranes, andcervical lymphadenopathy are the main symptoms.[11]

Small vessel vasculitis

[edit]

Small vessel vasculitis (SVV) is separated into immune complex SVV andantineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).[4]

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a necrotizing vasculitis linked to MPO-ANCA or PR3-ANCA that primarily affects small vessels and has few or no immune deposits. AAV is further classified aseosinophilic granulomatosis with polyangiitis,granulomatosis with polyangiitis, andmicroscopic polyangiitis.[4]

Eosinophilic granulomatosis with polyangiitis is a systemic small-vessel vasculitis linked toeosinophilia andasthma.Polyneuropathy, cardiac involvement, skin lesions, involvement of theupper respiratory tract, and lung are typical presentations ofeosinophilic granulomatosis with polyangiitis.[12]

Granulomatosis with polyangiitis, formerly known as Wegener's granulomatosis, is a rare immune-mediated systemic disease with an unclear etiology. It manifests pathologically as an inflammatory response pattern in the kidneys, upper and lowerrespiratory tracts, and granulomatous inflammation, which includesnecrosis.[13]

Microscopic polyangiitis belongs to the group of vasculitides associated with ANCA. Its distinct histology reveals a pauci-immune vasculitis, or necrotizing small vessel vasculitis, with minimal or no immune deposits.[14] The most typical features of microscopic polyangiitis are renal manifestations and general symptoms; lung involvement is also frequently observed.[15]

Immune complex small vessel vasculitis (SVV) is a vasculitis that primarily affects small vessels and has moderate to significantimmunoglobulin and complement component deposits on the vessel wall.[4] Hypocomplementemicurticarial vasculitis,cryoglobulinemic vasculitis,IgA vasculitis, andanti-glomerular basement membrane disease are the categories of immune complex SVV.[5]

Hypocomplementemicurticarial vasculitis syndrome is a rare immune complex-mediated condition that has persistent acquiredhypocomplementemia andurticaria. Many systemic manifestations are linked to hypocomplementemic urticarial vasculitis syndrome, such asleukocytoclastic vasculitis,glomerulonephritis,laryngeal edema, severeangioedema, pulmonary involvement,arthritis,arthralgia, anduveitis.[16]

Cryoglobulinemic vasculitis is a type of small-vessel vasculitis that primarily affects the kidneys, skin, joints, andperipheral nervous system. Monoclonalimmunoglobulins associated with an underlyingB-cell lymphoproliferative disorder are known as type I cryovalent vasculitis.Cryoglobulins type II and III, also known as mixedcryoglobulinemia, are composed of polyclonalimmunoglobulin (Ig)G and either monoclonalIgM or both withrheumatoid factor activity. The disease can present with a wide range of symptoms, from minor ones likefatigue,purpura, orarthralgia to more serious ones likeglomerulonephritis and widespread vasculitis that can be fatal.[17]

Immunoglobulin A (IgA) vasculitis, formerly referred to asHenoch–Schönlein purpura, is a type of immune complex vasculitis that primarily affectsIgA deposits in small vessels. Acuteenteritis,glomerulonephritis,arthralgias and/orarthritis, and cutaneouspurpura are the most common clinical manifestations. Children are more likely than adults to develop IgA vasculitis, and adults tend to have a more severe case.[18]

Anti-glomerular basement membrane disease is an uncommon kind of small vessel vasculitis that affects the kidney and lung capillary beds. This illness is also known by its eponym, "Goodpasture syndrome".[19]

Variable vessel vasculitis

[edit]

Variable vessel vasculitis is a kind of vasculitis that may impact vessels of all sizes (small, medium, and large) and any type (arteries,veins, andcapillaries), with no particular type of vessel being predominantly affected.[4] This category includesBehcet's disease andCogan's syndrome.[5]

Behçet's disease is a systemic illness marked by frequent episodes of severe inflammation. Genital ulcerations,uveitis, oral aphthous ulcers, and skin lesions are the main symptoms.[20]

Cogan's syndrome is an uncommon type of autoimmune systemic vasculitis that causes inflammation inside the eyes and malfunctions the vestibulo-auditory system, usually resulting inneurosensory deafness but alsotinnitus andvertigo.[21] Anupper respiratory tract infection, or less frequently,diarrhea, adental infection, or animmunization, precedes the onset of the disease.[22]

History

[edit]

Kussmaul and Maier gave the first detailed description of systemic necrotizing arteritis in 1866.[23]

In 1919Karl Theodor Fahr[24] described acute arteriallesions which were always present inmalignantnephrosclerosis. These injuries were the most severe and widespread in thekidneys and occurred less frequently and severely in otherorgans, particularly in thepancreas,adrenals andintestines. Fahr believed that necrotizing arteriolitis was the primary cause of the lesions, malignant necrosis andhypertension in these cases by narrowing the renalvascular bed.[23]

Signs and symptoms

[edit]

Prodromal symptoms, constitutional abnormalities, and organ-specific manifestations are common invasculitis patients. Patients may show up at the emergency room with life-threatening symptoms (such as massivehemoptysis orrenal failure) or with nonspecific signs and symptoms (such as arash,fever,myalgia,arthralgia,malaise, orweight loss) at their family physician's office. The size, location, and extent of the vessels involved all affect the manifestations.[25]

Takayasu arteritis (TA) is typically documented in three distinct phases. There are generalized constitutional inflammatory symptoms during the first stage. Patients may reportfever of unknown cause during this phase. Patients may refer to dorsal and thoracic pain in the following phase, and infrequently,neck pain as well.Arterial bruits, intermittent extremityclaudication, decreased or absent pulses, and/or variations in arterialblood pressure among upper extremities are the hallmarks of the final phase.[26]

Giant cell arteritis (GCA) often exhibits a wide range of symptoms in its early stages, all of which are related to the localized consequences of systemic and vascular inflammation. The symptoms of GCA includejaw claudication,headaches, and tenderness in the scalp. The most common symptom isheadache, which is restricted to the temporal region.[3]

Polyarteritis nodosa (PAN) can affect one organ or cause systemic failure as its clinical manifestation.[27] Although any tissue may be impacted, PAN rarely affects thelungs for unclear reasons.[28] A variety of clinical indicators, including common symptoms likefever,chills,weight loss,myalgia, andarthralgia, are typically present when PAN first manifests.Peripheral nerves and skin are typically involved in PAN. Skin manifestations includepurpura, necrotic ulcers, subcutaneous nodules, and livedoid.Mononeuritis multiplex is the main neurological symptom, typically presenting as a drop in the foot or wrist.[3]

Patients withKawasaki disease often have afever between 38 and 40 degrees Celsius and often show noprodromal symptoms. Within two to four days of the illness starting, bilateralconjunctival injections withoutexudate become visible. The term "modifications of the oral cavity" usually refers to conditions such as diffuseerythema of the oropharyngeal mucosa, strawberry-like tongue without vesicles or pseudo-membrane formation, bleeding of the lips, redness, fissuring, and dryness. From the first to the fifth day following the onset of fever, polymorphouserythema appears on the body and/or extremities.[3]

Malaise,arthralgia,sinusitis, andrhinitis are typically present at the beginning ofAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.Prodromes often occur weeks or months beforepulmonary-renal syndrome.[3]

Anti-glomerular basement membrane vasculitis patients usually report sudden onset ofanuria oroliguria. Typically,hematuria or tea-colored urine are noticed.[3]

Many cases ofcryoglobulinemia vasculitis are asymptomatic.[29]Hyperviscosity and/orthrombosis are the principal signs and symptoms of type Icryoglobulinemia. As a result, the conditions most frequently manifested asRaynaud's phenomenon, distalgangrene, ischemic ulcers,purpura,livedo reticularis,headache, retinal hemorrhages, andencephalopathy. Nonspecific systemic and musculoskeletal symptoms, such ascutaneous vasculitis andneuropathy, can also be seen in patients with mixed cryoglobulinemia.[30]

Ninety-five percent of cases ofimmunoglobulin A vasculitis start with a skin rash.[31] Additionally, the illness manifests as the standard tripartite of symptoms pertaining to the gastrointestinal, renal, and musculoskeletal systems.[32]

Recurrenturticaria, with skin eruptions primarily affecting the trunk, face, and upper extremities, is the primary clinical manifestation of hypocomplementemicurticarial vasculitis.[33]

Oralaphthae are the defining feature ofBehçet's disease and manifest in 98% of patients. Compared to oral lesions, genital aphthae are less common.[3]

Often, theupper respiratory tract infection is the initial sign of Cogan's syndrome.[3] Ocular and audio-vestibular symptoms are typical indicators. Non-syphiliticinterstitial keratitis (IK),uveitis,retinal vasculitis,conjunctivitis,scleritis,tinnitus,hearing loss, andvertigo are among the range of ocular manifestations.[34]

Diagnosis

[edit]

To confirm the diagnosis, the initial evaluation consists of a thorough clinical assessment,serological tests,histology when possible, andradiography when necessary.[35]

Individuals experiencing activevasculitis frequently exhibitanemia,thrombocytopenia, andleukocytosis. One of the main characteristics ofeosinophilic granulomatosis with polyangiitis iseosinophilia.[25]

Patients with vasculitis frequently have increasederythrocyte sedimentation rate and elevatedC-reactive protein levels; however, these symptoms are nonspecific and can arise in a variety of circumstances, most notably infection. When vasculitis is not active, normalerythrocyte sedimentation rate orC-reactive protein level can occur and should not rule out the diagnosis. When paired with congruent clinical features, an elevatederythrocyte sedimentation rate ingiant cell arteritis patients can both support the diagnosis and aid in disease monitoring.[25]

In any patient suspected of havingvasculitis, measurements ofblood urea nitrogen,serum creatinine, and urine should be taken.Hematuria andproteinuria raise the risk ofglomerulonephritis.Serum bilirubin andliver enzyme levels (ó-glutamyltransferase,alkaline phosphatase, andaspartate andalanine transaminase) can give indications for liver-related vasculitis, likepolyarteritis nodosa.[25]

Antineutrophil cytoplasmic antibodies (ANCAs) are a diverse collection ofautoantibodies that targetneutrophil enzymes and have been detected in the serum of many vasculitis patients. The conditions known as ANCA-associated vasculitides, which are characterized by circulating ANCAs, comprisegranulomatosis with polyangiitis,microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.[25]

Chest radiography may reveal nonspecific abnormalities such ascardiomegaly, patchy consolidation, nodules, and infiltrates. These results can happen in a variety of situations, but if they go undiagnosed, they could point to vasculitis.[25]

Aneurysms andvascular occlusion can be seen withangiography.Polyarteritis nodosa can be verified by looking foraneurysms in therenal andmesenteric arteries. While conventionalangiography remains the accepted standard diagnostic modality, there is potential for superiority withcomputed tomography angiography andmagnetic resonance angiography, as they can offer important insights into intraluminal pathology and vessel wall thickening. These methods have been applied toKawasaki disease andTakayasu arteritis diagnosis and follow-up.[25]

WhenKawasaki disease is present,transthoracic echocardiography can identify coronary artery abnormalities.[25]Echocardiography reveals coronary artery lesions (ectasia oraneurysm) in about 40% of children withKawasaki disease.[36] In patients withTakayasu arteritis,echocardiography is used to measure the degree of coronarystenosis andcoronary artery blood flow.[37]

For the diagnosis and ongoing observation of large vessel vasculitis,ultrasonography may be helpful. Individuals diagnosed withgiant cell arteritis may present with superficial temporal arterystenosis, occlusion, or halo sign (a dark patch surrounding the artery due to vessel walledema).[25]

When diagnosing patients withgranulomatosis with polyangiitis,computed tomography is useful. Results include destruction of punctate bone, primarily in the midline, and thickening of thenasal mucosa.[25] In about 90% of patients with granulomatosis with polyangiitis, a chest computed tomography scan will show nodules or masses.[38]

Systemic vasculitides, such aspolyarteritis nodosa,granulomatosis with polyangiitis, andeosinophilic granulomatosis with polyangiitis, can result in motor andsensory neuropathy. Neurological manifestations should be evaluated bynerve conduction testing.[25]

Abiopsy of the affected tissue (such as the skin, the sinuses, lung, artery, nerve, or kidney) is used to make a definitive diagnosis of vasculitis by identifying the pattern of vessel inflammation. Determining the precise type of vasculitis may be made easier by looking forimmunoglobulins and complement on the tissue section as detected byimmunofluorescence. Although a negative biopsy cannot rule out vasculitis, biopsies are especially useful in ruling out other causes.[25]

Treatment

[edit]

Treatment is targeted at the underlying cause. However, most vasculitides, in general, are treated withsteroids (e.g.,methylprednisolone) because the underlying cause of the vasculitis is due to hyperactive immunological damage. Immunosuppressants such ascyclophosphamide andazathioprine may also be given.

Asystematic review ofantineutrophil cytoplasmic antibody-positive vasculitis identified the best treatments depending on whether the goal is to induce remission or maintenance and depending on the severity of the vasculitis.[39]

References

[edit]
  1. ^Cruz BA, Ramanoelina J, Mahr A, et al. (October 2003)."Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit".Rheumatology.42 (10):1183–8.doi:10.1093/rheumatology/keg322.PMID 12777637.
  2. ^abcVashi, Falguni (2014). "Vascular System and Hematology".Acute Care Handbook for Physical Therapists. Elsevier. pp. 161–199.doi:10.1016/b978-1-4557-2896-1.00007-x.ISBN 978-1-4557-2896-1.
  3. ^abcdefghRalli, Massimo; Campo, Flaminia; Angeletti, Diletta; Minni, Antonio; Artico, Marco; Greco, Antonio; Polimeni, Antonella; Vincentiis, Marco de (2020)."Pathophysiology and therapy of systemic vasculitides".EXCLI Journal.19. Leibniz Research Centre for Working Environment and Human Factors:817–854.doi:10.17179/excli2020-2510.PMC 7355154.PMID 32665772.
  4. ^abcdefJennette, J. C.; Falk, R. J.; Bacon, P. A.; Basu, N.; Cid, M. C.; Ferrario, F.; Flores-Suarez, L. F.; Gross, W. L.; Guillevin, L.; Hagen, E. C.; Hoffman, G. S.; Jayne, D. R.; Kallenberg, C. G. M.; Lamprecht, P.; Langford, C. A.; Luqmani, R. A.; Mahr, A. D.; Matteson, E. L.; Merkel, P. A.; Ozen, S.; Pusey, C. D.; Rasmussen, N.; Rees, A. J.; Scott, D. G. I.; Specks, U.; Stone, J. H.; Takahashi, K.; Watts, R. A. (December 27, 2012)."2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides".Arthritis & Rheumatism.65 (1). Wiley:1–11.doi:10.1002/art.37715.hdl:11655/14109.ISSN 0004-3591.PMID 23045170.
  5. ^abcdJennette, J. Charles (September 27, 2013)."Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides".Clinical and Experimental Nephrology.17 (5). Springer Science and Business Media LLC:603–606.doi:10.1007/s10157-013-0869-6.ISSN 1342-1751.PMC 4029362.PMID 24072416.
  6. ^Kerr, Gail S. (1994-06-01). "Takayasu Arteritis".Annals of Internal Medicine.120 (11):919–929.doi:10.7326/0003-4819-120-11-199406010-00004.ISSN 0003-4819.PMID 7909656.S2CID 21784938.
  7. ^Johnston, S L; Lock, R J; Gompels, M M (July 1, 2002)."Takayasu arteritis: a review".Journal of Clinical Pathology.55 (7). BMJ:481–486.doi:10.1136/jcp.55.7.481.ISSN 0021-9746.PMC 1769710.PMID 12101189.
  8. ^Hall, S; Barr, W; Lie, J T; Stanson, A W; Kazmier, F J; Hunder, G G (March 1985). "Takayasu arteritis. A study of 32 North American patients".Medicine.64 (2):89–99.doi:10.1097/00005792-198503000-00002.PMID 2858047.
  9. ^Levine, Stuart M.; Hellmann, David B. (2002). "Giant cell arteritis".Current Opinion in Rheumatology.14 (1). Ovid Technologies (Wolters Kluwer Health):3–10.doi:10.1097/00002281-200201000-00002.ISSN 1040-8711.PMID 11790989.
  10. ^De Virgilio, Armando; Greco, Antonio; Magliulo, Giuseppe; Gallo, Andrea; Ruoppolo, Giovanni; Conte, Michela; Martellucci, Salvatore; de Vincentiis, Marco (2016). "Polyarteritis nodosa: A contemporary overview".Autoimmunity Reviews.15 (6). Elsevier BV:564–570.doi:10.1016/j.autrev.2016.02.015.ISSN 1568-9972.PMID 26884100.
  11. ^Hedrich, Christian M.; Schnabel, Anja; Hospach, Toni (July 10, 2018)."Kawasaki Disease".Frontiers in Pediatrics.6 198.doi:10.3389/fped.2018.00198.ISSN 2296-2360.PMC 6048561.PMID 30042935.
  12. ^Villa-Forte, A (January 2023). "Eosinophilic granulomatosis with polyangiitis".Postgraduate Medicine.135 (Supplement 1):52–60.doi:10.1080/00325481.2022.2134624.PMID 36259957.
  13. ^Greco, A; Marinelli, C; Fusconi, M; Macri, Gf; Gallo, A; De Virgilio, A; Zambetti, G; de Vincentiis, M (2016)."Clinic manifestations in granulomatosis with polyangiitis".International Journal of Immunopathology and Pharmacology.29 (2):151–159.doi:10.1177/0394632015617063.ISSN 2058-7384.PMC 5806708.PMID 26684637.
  14. ^Villiger, Peter M.; Guillevin, Loïc (2010). "Microscopic polyangiitis: Clinical presentation".Autoimmunity Reviews.9 (12). Elsevier BV:812–819.doi:10.1016/j.autrev.2010.07.009.ISSN 1568-9972.PMID 20656070.
  15. ^Oh, Ji Seon; Lee, Chang-Keun; Kim, Yong Gil; Nah, Seong-Su; Moon, Hee-Bom; Yoo, Bin (2009)."Clinical Features and Outcomes of Microscopic Polyangiitis in Korea".Journal of Korean Medical Science.24 (2). XMLink:269–274.doi:10.3346/jkms.2009.24.2.269.ISSN 1011-8934.PMC 2672127.PMID 19399269.
  16. ^Jara, Luis J.; Navarro, Carmen; Medina, Gabriela; Vera-Lastra, Olga; Saavedra, Miguel A. (2009). "Hypocomplementemic urticarial vasculitis syndrome".Current Rheumatology Reports.11 (6):410–415.doi:10.1007/s11926-009-0060-y.ISSN 1523-3774.PMID 19922730.S2CID 30498070.
  17. ^Cacoub, Patrice; Comarmond, Cloe; Domont, Fanny; Savey, Léa; Saadoun, David (2015)."Cryoglobulinemia Vasculitis"(PDF).The American Journal of Medicine.128 (9). Elsevier BV:950–955.doi:10.1016/j.amjmed.2015.02.017.ISSN 0002-9343.PMID 25837517.S2CID 12560858.
  18. ^Audemard-Verger, Alexandra; Pillebout, Evangeline; Guillevin, Loïc; Thervet, Eric; Terrier, Benjamin (2015). "IgA vasculitis (Henoch–Shönlein purpura) in adults: Diagnostic and therapeutic aspects".Autoimmunity Reviews.14 (7). Elsevier BV:579–585.doi:10.1016/j.autrev.2015.02.003.ISSN 1568-9972.PMID 25688001.
  19. ^McAdoo, Stephen P.; Pusey, Charles D. (May 17, 2017)."Anti-Glomerular Basement Membrane Disease".Clinical Journal of the American Society of Nephrology.12 (7). Ovid Technologies (Wolters Kluwer Health):1162–1172.doi:10.2215/cjn.01380217.ISSN 1555-9041.PMC 5498345.PMID 28515156.
  20. ^Kurokawa, Manae S; Yoshikawa, Hideshi; Suzuki, Noboru (2004). "Behçet's Disease".Seminars in Respiratory and Critical Care Medicine (in German).25 (5):557–568.doi:10.1055/s-2004-836147.ISSN 1069-3424.PMID 16088499.S2CID 6138974.
  21. ^Iliescu, Daniela Adriana; Timaru, Cristina Mihaela; Batras, Mehdi; Simone, Algerino De; Stefan, Cornel (2015)."Cogan's Syndrome".Romanian Journal of Ophthalmology.59 (1). Romanian Society of Ophthalmology:6–13.PMC 5729811.PMID 27373108.
  22. ^Grasland, A. (June 1, 2004). "Typical and atypical Cogan's syndrome: 32 cases and review of the literature".Rheumatology.43 (8). Oxford University Press (OUP):1007–1015.doi:10.1093/rheumatology/keh228.ISSN 1460-2172.PMID 15150435.
  23. ^ab"Pathogenesis of Hypertensive Arterial Necrosis".JAMA.141 (4): 4. September 24, 1949.doi:10.1001/jama.1949.02910040028008.
  24. ^R. Mellon, Ralph; R. Baker, Margaret; P. Mclroy, Alice (1935)."Experimental Necrotizing Arteriolitis Induced by a Protein Cleavage Product".Experimental Biology and Medicine.33:92–95.doi:10.3181/00379727-33-8263C. Retrieved24 August 2025.
  25. ^abcdefghijklSharma, Poonam; Sharma, Sanjeev; Baltaro, Richard; Hurley, John (March 1, 2011)."Systemic Vasculitis".American Family Physician.83 (5):556–565.PMID 21391523. RetrievedJanuary 17, 2024.
  26. ^KESER, Gökhan; AKSU, Kenan; DİRESKENELİ, Haner (August 16, 2018). "Takayasu arteritis: an update".Turkish Journal of Medical Sciences.48 (4). The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS:681–697.doi:10.3906/sag-1804-136.hdl:11424/219927.ISSN 1300-0144.PMID 30114347.S2CID 52014268.
  27. ^Howard, Travis; Ahmad, Kinza; Swanson, Jerome (Allen) A.; Misra, Sanjay (2014)."Polyarteritis Nodosa".Techniques in Vascular and Interventional Radiology.17 (4). Elsevier BV:247–251.doi:10.1053/j.tvir.2014.11.005.ISSN 1089-2516.PMC 4363102.PMID 25770638.
  28. ^Springer, JM; Byram, K (January 2023). "Polyarteritis nodosa: an evolving primary systemic vasculitis".Postgraduate Medicine.135 (Supplement 1):61–68.doi:10.1080/00325481.2022.2088940.PMID 35709399.
  29. ^TREJO, OLGA; RAMOS-CASALS, MANUEL; GARCÍA-CARRASCO, MARIO; YAGÜE, JORDI; JIMÉNEZ, SÒNIA; DE LA RED, GLORIA; CERVERA, RICARD; FONT, JOSEP; INGELMO, MIGUEL (2001). "Cryoglobulinemia".Medicine.80 (4). Ovid Technologies (Wolters Kluwer Health):252–262.doi:10.1097/00005792-200107000-00004.ISSN 0025-7974.PMID 11470986.
  30. ^Ramos-Casals, Manuel; Trejo, Olga; García-Carrasco, Mario; Cervera, Ricard; Font, Josep (2000). "Mixed cryoglobulinemia: new concepts".Lupus.9 (2). SAGE Publications:83–91.doi:10.1191/096120300678828127.ISSN 0961-2033.PMID 10787003.S2CID 19390158.
  31. ^Nong, Bao-Ren; Huang, Yung-Feng; Chuang, Chih-Ming; Liu, Chia-Chia; Hsieh, Kai-Sheng (August 2007). "Fifteen-year experience of children with Henoch-Schönlein purpura in southern Taiwan, 1991-2005".Journal of Microbiology, Immunology, and Infection.40 (4):371–376.PMID 17712473.
  32. ^Eleftheriou, Despina; Brogan, Paul A. (2009)."Vasculitis in children".Best Practice & Research Clinical Rheumatology.23 (3). Elsevier BV:309–323.doi:10.1016/j.berh.2009.02.001.ISSN 1521-6942.PMC 7106032.PMID 19508940.
  33. ^Buck, Andrew; Christensen, Jim; McCarty, Morgan (2012)."Hypocomplementemic Urticarial Vasculitis Syndrome: A Case Report and Literature Review".The Journal of Clinical and Aesthetic Dermatology.5 (1). Matrix Medical Communications:36–46.PMC 3277093.PMID 22328958.
  34. ^Kessel, Aharon; Vadasz, Zahava; Toubi, Elias (2014). "Cogan syndrome — Pathogenesis, clinical variants and treatment approaches".Autoimmunity Reviews.13 (4–5). Elsevier BV:351–354.doi:10.1016/j.autrev.2014.01.002.ISSN 1568-9972.PMID 24418297.
  35. ^Miller, Anne; Basu, Neil; Luqmani, Raashid (2008). "Assessment of systemic vasculitis".Autoimmunity Reviews.8 (2). Elsevier BV:170–175.doi:10.1016/j.autrev.2008.07.001.ISSN 1568-9972.PMID 18672099.
  36. ^Baer, Aryeh Z.; Rubin, Lorry G.; Shapiro, Craig A.; Sood, Sunil K.; Rajan, Sujatha; Shapir, Yehuda; Romano, Angela; Bierman, Fredrick Z. (July 1, 2006). "Prevalence of Coronary Artery Lesions on the Initial Echocardiogram in Kawasaki Syndrome".Archives of Pediatrics & Adolescent Medicine.160 (7). American Medical Association (AMA):686–690.doi:10.1001/archpedi.160.7.686.ISSN 1072-4710.PMID 16818833.S2CID 32194867.
  37. ^Espinola-Zavaleta, Nilda; Soto, María Elena; Bauk, Lucas; Miguel Casanova, José; Keirns, Candace; Vanzzini, Nydia Avila; Reyes, Pedro (2005). "Coronary Reserve in Takayasu's Arteritis: Transesophageal Echocardiographic Analysis".Echocardiography.22 (7). Wiley:593–598.doi:10.1111/j.1540-8175.2005.40105.x.ISSN 0742-2822.PMID 16060896.
  38. ^Nataraja, Anjali; Mukhtyar, Chetan; Hellmich, Bernhard; Langford, Carol; Luqmani, Raashid (2007). "Outpatient assessment of systemic vasculitis".Best Practice & Research Clinical Rheumatology.21 (4). Elsevier BV:713–732.doi:10.1016/j.berh.2007.01.004.ISSN 1521-6942.PMID 17678832.
  39. ^Bosch X, Guilabert A, Espinosa G, Mirapeix E (2007)."Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review".JAMA.298 (6):655–69.doi:10.1001/jama.298.6.655.PMID 17684188.

Further reading

[edit]

1940s Papers

[edit]
  • Goldblatt, Harry (1940). "Extrarenal arteriolar necrosis and necrotizing arteriolitis".American Association for the Advancement of Science. Blood, Heart and Circulation.:266–273.
  • Wilson, C; Pickering, G. W. (15 August 1938). "Acute Arterial Lesions in Rabbits with Experimental Renal Hypertension".Clinical Science.3:343–355.
  • Byrom, F. B.; Dodson, L. F. (July 1948). "The causation of acute arterial necrosis in hypertensive disease".The Journal of Pathology and Bacteriology.60 (3):357–368.doi:10.1002/path.1700600302.

2020s Papers

[edit]
  • Saha MK, Pendergraft WF, Jennette C, Falk RJ. Primaryu glomerular disease.Brenner and Rector's The Kidney. 11th ed. Philadelphia, PA: Elsevier; 2020 chap 31.
  • Free M, Jennette JC, Falk RJ, Jain K. Renal and systemic vasculitis.Comprehensive Clinical Nephrology. 7th ed. Philadelphia, PA: Elsevier; 2024 chap 26.
  • Dinulos JGH. Hypersensitivity syndromes and vasculitis. Habif's Clinical Dermatology. 7th ed. Philadelphia, PA: Elsevier; 2021 chap 18.

External links

[edit]
Classification
External resources
Large vessel
Medium vessel
Small vessel
Pauci-immune
Type III hypersensitivity
Ungrouped
Other
Retrieved from "https://en.wikipedia.org/w/index.php?title=Systemic_vasculitis&oldid=1318385391"
Category:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp